Enoticumab, binding human Dll4 and disrupting Notch-mediated signaling, had antitumor activity in molecular- and angiogenesis-relevant scenarios in ovarian cancer and other solid tumors (28). The gene discussed is DLL4; the disease is ovarian cancer.